Overview
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company. It develops small molecule therapies for patients living with cancer and genetic disease. The company has announced participation in two major investor conferences in March 2026. These events offer investors, analysts, and healthcare professionals direct access to the company’s leadership team.
Relay Therapeutics continues to advance its oncology and rare disease programs. These fireside chat appearances reflect the company’s commitment to transparent communication with its stakeholders. They also highlight the company’s growing prominence in the biotech sector.
TD Cowen 46th Annual Health Care Conference
Event Details
The first conference appearance takes place at the TD Cowen 46th Annual Health Care Conference:
- Date: Monday, March 2, 2026
- Time: 3:10 p.m. ET
- Format: Fireside Chat (Live Webcast)
What to Expect
The TD Cowen Annual Health Care Conference ranks among the most prestigious gatherings in life sciences investing. It draws leading executives, institutional investors, and healthcare analysts from around the world. Relay Therapeutics’ management team will participate in a focused fireside chat. This format allows for direct discussion on clinical programs, strategic priorities, and near-term catalysts.
For Relay Therapeutics, whose pipeline is moving through critical clinical stages, this appearance sends a clear message. It signals management’s confidence in the company’s direction and pipeline readiness. Investors will watch closely for any updates on trial timelines and enrollment.
Barclays 28th Annual Global Healthcare Conference
Event Details
The second conference appearance is at the Barclays 28th Annual Global Healthcare Conference:
- Date: Wednesday, March 11, 2026
- Time: 10:30 a.m. ET
- Format: Fireside Chat (Live Webcast)
Why This Forum Matters
The Barclays Global Healthcare Conference brings together top voices in biopharma and healthcare investing. Relay Therapeutics’ management participation reinforces the company’s active engagement with the investment community. Furthermore, the event provides a platform to address questions about clinical progress, regulatory strategy, and commercial planning. Both conferences occur at a pivotal time, with the company’s lead asset advancing in Phase 3.
How to Access the Webcasts
Live Streaming and Replay Options
Both fireside chats will stream live through Relay Therapeutics’ official Investor Relations website. Viewers can find event links under the Events section within the News & Events portal.
Additionally, an archived replay of each webcast will remain available for up to 30 days after each event. This ensures stakeholders who miss the live broadcast can still access discussions at their convenience. This accessibility reflects Relay Therapeutics’ commitment to keeping all stakeholders informed year-round.
About Relay Therapeutics
Company Background
Relay Therapeutics is a clinical-stage, small molecule precision medicine company. Its focus is developing therapies that can transform outcomes for patients with cancer and genetic disease. The company’s cornerstone technology, the Dynamo® platform, integrates advanced computational and experimental approaches. It targets proteins that were previously considered undruggable or inadequately addressed by existing therapies.
This combination of data science, structural biology, and drug design sets Relay Therapeutics apart. As a result, the company has built a reputation as a true innovator in the precision medicine space.
Pipeline Highlights
Zovegalisib — Lead Clinical Asset
Relay Therapeutics’ most advanced program centers on zovegalisib. It holds the distinction of being the first pan-mutant selective PI3Kα inhibitor to enter clinical development. Moreover, zovegalisib is currently under evaluation in the Phase 3 ReDiscover-2 clinical trial. The trial focuses on patients with HR+/HER2- metastatic breast cancer — one of the most common and difficult-to-treat forms of the disease.
PI3Kα-Driven Vascular Anomalies
Beyond oncology, zovegalisib also shows promise as a treatment for PI3Kα-driven vascular anomalies. These are rare genetic conditions with very limited treatment options. This dual application demonstrates the versatility of Relay’s approach to drug development.
Additional Pipeline Programs
Relay’s pipeline extends further with targeted programs for:
- NRAS-driven solid tumors — targeting an aggressive mutation found across several cancer types
- Fabry disease — a rare inherited lysosomal storage disorder with significant unmet medical need
Together, these programs give Relay Therapeutics a well-rounded and differentiated pipeline. The company addresses both high-prevalence and rare disease indications, which strengthens its long-term value proposition.
Why These Conferences Matter
Strategic Investor Visibility
Investor conferences hosted by TD Cowen and Barclays serve as critical platforms for biotech companies. They allow management to communicate their value proposition directly to institutional investors and analysts. For Relay Therapeutics, these events come at a pivotal moment. Market participants are watching closely for updates on the ReDiscover-2 trial, enrollment status, and pipeline readiness.
Building Confidence in a Critical Year
With zovegalisib in Phase 3 and the broader pipeline maturing, 2026 is shaping up as a defining year for Relay Therapeutics. Active participation in two major investor forums signals management confidence. It also demonstrates transparency and proactive communication — qualities that investors value highly in clinical-stage biopharmaceutical companies. Therefore, these appearances carry strategic weight beyond simple visibility.
Conclusion
Relay Therapeutics’ appearances at the TD Cowen 46th Annual Health Care Conference on March 2 and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, represent key moments for the company. With its groundbreaking Dynamo® platform, a Phase 3 oncology trial underway, and a diverse rare disease pipeline, Relay Therapeutics continues to build its case as a compelling biotech story. Investors and stakeholders should tune into the live webcasts or access replays via the company’s IR website within 30 days of each event.
